JP2020522266A5 - - Google Patents

Download PDF

Info

Publication number
JP2020522266A5
JP2020522266A5 JP2019566965A JP2019566965A JP2020522266A5 JP 2020522266 A5 JP2020522266 A5 JP 2020522266A5 JP 2019566965 A JP2019566965 A JP 2019566965A JP 2019566965 A JP2019566965 A JP 2019566965A JP 2020522266 A5 JP2020522266 A5 JP 2020522266A5
Authority
JP
Japan
Prior art keywords
seq
nos
region
antibody
protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2019566965A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020522266A (ja
JP7710827B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2018/053997 external-priority patent/WO2018224951A2/en
Publication of JP2020522266A publication Critical patent/JP2020522266A/ja
Publication of JP2020522266A5 publication Critical patent/JP2020522266A5/ja
Application granted granted Critical
Publication of JP7710827B2 publication Critical patent/JP7710827B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2019566965A 2017-06-05 2018-06-04 非対称なｃｈ２－ｃｈ３領域の変異を有する、操作された多重特異性抗体及び他の多量体タンパク質 Active JP7710827B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762515316P 2017-06-05 2017-06-05
US62/515,316 2017-06-05
PCT/IB2018/053997 WO2018224951A2 (en) 2017-06-05 2018-06-04 Engineered multispecific antibodies and other multimeric proteins with asymmetrical ch2-ch3 region mutations

Publications (3)

Publication Number Publication Date
JP2020522266A JP2020522266A (ja) 2020-07-30
JP2020522266A5 true JP2020522266A5 (enExample) 2021-07-26
JP7710827B2 JP7710827B2 (ja) 2025-07-22

Family

ID=64458754

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019566965A Active JP7710827B2 (ja) 2017-06-05 2018-06-04 非対称なｃｈ２－ｃｈ３領域の変異を有する、操作された多重特異性抗体及び他の多量体タンパク質

Country Status (10)

Country Link
US (1) US11149094B2 (enExample)
EP (1) EP3634486A4 (enExample)
JP (1) JP7710827B2 (enExample)
KR (1) KR20200014379A (enExample)
CN (1) CN110785185B (enExample)
AU (1) AU2018281045A1 (enExample)
BR (1) BR112019025583A2 (enExample)
CA (1) CA3065171A1 (enExample)
MX (1) MX2019014576A (enExample)
WO (1) WO2018224951A2 (enExample)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT3434767T (pt) 2010-11-30 2026-01-23 Chugai Pharmaceutical Co Ltd Agente terapêutico indutor de citotoxicidade
AU2012262007B2 (en) 2011-06-02 2017-06-22 Takeda Pharmaceutical Company Limited Fc receptor binding proteins
CN109134658B (zh) 2011-10-31 2022-10-14 中外制药株式会社 控制了重链与轻链的缔合的抗原结合分子
WO2016087650A1 (en) * 2014-12-05 2016-06-09 Merck Patent Gmbh Domain-exchanged antibody
US11254744B2 (en) * 2015-08-07 2022-02-22 Imaginab, Inc. Antigen binding constructs to target molecules
CN108779182A (zh) * 2015-12-28 2018-11-09 麻省理工学院 具有恒定区突变的双特异性抗体及其用途
WO2018119142A1 (en) 2016-12-21 2018-06-28 Amgen Inc. Anti-tnf alpha antibody formulations
US11266745B2 (en) 2017-02-08 2022-03-08 Imaginab, Inc. Extension sequences for diabodies
JOP20190248A1 (ar) 2017-04-21 2019-10-20 Amgen Inc بروتينات ربط مولد ضد trem2 واستخداماته
CA3066918A1 (en) 2017-06-12 2018-12-20 Bluefin Biomedicine, Inc. Anti-il1rap antibodies and antibody drug conjugates
KR102611853B1 (ko) * 2017-06-30 2023-12-08 자임워크스 비씨 인코포레이티드 안정화된 키메라 fabs
PE20210005A1 (es) 2017-09-29 2021-01-05 Chugai Pharmaceutical Co Ltd Molecula de union al antigeno multiespecifica que tiene actividad de sustitucion de la funcion de cofactor del factor viii de coagulacion de sangre (fviii) y formulacion farmaceutica que contiene tal molecula como ingrediente activo
WO2020259535A1 (zh) * 2019-06-25 2020-12-30 南京金斯瑞生物科技有限公司 抗cd47/抗tigit双特异抗体及其制备方法和应用
AU2020310174A1 (en) * 2019-07-09 2022-02-03 Tavotek Biotherapeutics (Hong Kong) Limited Bispecific antibodies to TNF-alpha and IL-1beta and uses thereof
US20220259309A1 (en) * 2019-07-17 2022-08-18 Bioinvent International Ab Antibody combinations for treatment of cancer in specific patients
US20220306735A1 (en) * 2019-08-30 2022-09-29 University Of Kansas Compositions including igg fc mutations and uses thereof
CN114929750B (zh) 2019-09-13 2024-11-22 芝加哥大学 用于治疗葡萄球菌感染的方法和组合物
JP7842011B2 (ja) * 2019-09-27 2026-04-07 アジェナス インコーポレイテッド ヘテロ二量体タンパク質
WO2021143826A1 (zh) * 2020-01-17 2021-07-22 信达生物制药(苏州)有限公司 重组抗程序性死亡受体1和抗分化抗原簇137双特异性抗体制剂及其用途
CN115768454A (zh) * 2020-02-07 2023-03-07 安万托特性材料股份有限公司 多肽亲和配体及其应用方法
BR112022018452A2 (pt) * 2020-03-25 2022-11-01 Lilly Co Eli Proteínas de ligação multiespecíficas e métodos de desenvolvimento das mesmas
US11987640B2 (en) * 2020-04-07 2024-05-21 Fred Hutchinson Cancer Center Anti-mesothelin antigen-binding molecules and uses thereof
WO2022094009A1 (en) * 2020-10-30 2022-05-05 The Government Of The United States Of America, As Represented By The Secretary Of The Navy Single domain antibodies to sars-cov-2 nucleocapsid protein
EP4435107A4 (en) * 2021-11-29 2025-12-31 Tosoh Corp ANTIBODY ISOLATION METHOD
CN116178546B (zh) * 2022-10-13 2024-06-18 深圳市百士通科技开发有限公司 一种多功能重组抗体及其制备方法和应用
KR20250122541A (ko) 2022-10-25 2025-08-13 사이즈믹 테라퓨틱, 인코포레이티드. 변이체 IgG FC 폴리펩티드 및 그 용도
WO2024213119A1 (en) * 2023-04-14 2024-10-17 Adaptocue, Llc Ph-sensitive cd47-binding domains and uses thereof
GB202311984D0 (en) * 2023-08-04 2023-09-20 Petmedix Ltd Optimised fc molecules
WO2026078231A1 (en) 2024-10-11 2026-04-16 T-Therapeutics Limited Soluble non-aggregating immune ligand

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0281604B1 (en) 1986-09-02 1993-03-31 Enzon Labs Inc. Single polypeptide chain binding molecules
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
US6172197B1 (en) 1991-07-10 2001-01-09 Medical Research Council Methods for producing members of specific binding pairs
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US6255458B1 (en) 1990-08-29 2001-07-03 Genpharm International High affinity human antibodies and human antibodies against digoxin
PT1024191E (pt) 1991-12-02 2008-12-22 Medical Res Council Produção de auto-anticorpos a partir de reportórios de segmentos de anticorpo e exibidos em fagos
ES2156149T3 (es) 1992-12-04 2001-06-16 Medical Res Council Proteinas de union multivalente y multiespecificas, su fabricacion y su uso.
AUPO591797A0 (en) 1997-03-27 1997-04-24 Commonwealth Scientific And Industrial Research Organisation High avidity polyvalent and polyspecific reagents
US7951917B1 (en) 1997-05-02 2011-05-31 Genentech, Inc. Method for making multispecific antibodies having heteromultimeric and common components
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
CA2430013C (en) 2000-11-30 2011-11-22 Medarex, Inc. Transgenic transchromosomal rodents for making human antibodies
WO2005047327A2 (en) * 2003-11-12 2005-05-26 Biogen Idec Ma Inc. NEONATAL Fc RECEPTOR (FcRn)-BINDING POLYPEPTIDE VARIANTS, DIMERIC Fc BINDING PROTEINS AND METHODS RELATED THERETO
CN101189028B (zh) * 2004-07-12 2013-05-29 马克罗基因公司 具有变异Fc区的抗体的鉴定和工程化以及使用方法
AU2005274905B2 (en) * 2004-08-04 2010-12-23 Mentrik Biotech, Llc Variant Fc regions
AU2005304624B2 (en) * 2004-11-12 2010-10-07 Xencor, Inc. Fc variants with altered binding to FcRn
US8802820B2 (en) 2004-11-12 2014-08-12 Xencor, Inc. Fc variants with altered binding to FcRn
US20110123440A1 (en) * 2005-03-29 2011-05-26 Genevieve Hansen Altered Antibody FC Regions and Uses Thereof
AU2006232287B2 (en) 2005-03-31 2011-10-06 Chugai Seiyaku Kabushiki Kaisha Methods for producing polypeptides by regulating polypeptide association
DE102005028778A1 (de) 2005-06-22 2006-12-28 SUNJÜT Deutschland GmbH Mehrlagige Folie mit einer Barriere- und einer antistatischen Lage
AU2007254853B2 (en) 2006-06-02 2011-11-17 Aveo Pharmaceuticals, Inc. Hepatocyte growth factor (HGF) binding proteins
JP2009541275A (ja) 2006-06-22 2009-11-26 ノボ・ノルデイスク・エー／エス 二重特異性抗体の生産
US20080112961A1 (en) * 2006-10-09 2008-05-15 Macrogenics, Inc. Identification and Engineering of Antibodies with Variant Fc Regions and Methods of Using Same
WO2008114011A2 (en) * 2007-03-19 2008-09-25 Medimmune Limited Fc polypeptide variants obtained by ribosome display methodology
AU2008343589A1 (en) 2007-12-19 2009-07-09 Centocor Ortho Biotech Inc. Design and generation of human de novo pIX phage display libraries via fusion to pIX or pVII, vectors, antibodies and methods
WO2010129304A2 (en) 2009-04-27 2010-11-11 Oncomed Pharmaceuticals, Inc. Method for making heteromultimeric molecules
MY192182A (en) * 2009-06-26 2022-08-04 Regeneron Pharma Readily isolated bispecific antibodies with native immunoglobulin format
JP2012532608A (ja) 2009-07-08 2012-12-20 アムジェン インコーポレイテッド ＣＨ３ドメイン界面操作を通じた、安定でそして凝集しない抗体Ｆｃ分子の設計
TWI667257B (zh) * 2010-03-30 2019-08-01 中外製藥股份有限公司 促進抗原消失之具有經修飾的ＦｃＲｎ親和力之抗體
ES2758994T3 (es) 2010-11-05 2020-05-07 Zymeworks Inc Diseño anticuerpo heterodimérico estable con mutaciones en el dominio Fc
EP2647706B1 (en) * 2010-11-30 2023-05-17 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule capable of binding to plurality of antigen molecules repeatedly
MX352889B (es) * 2011-02-25 2017-12-13 Chugai Pharmaceutical Co Ltd Anticuerpo de fc especifico para fcyriib.
KR102276528B1 (ko) * 2011-09-30 2021-07-12 추가이 세이야쿠 가부시키가이샤 이온 농도 의존성 결합 분자 라이브러리
JP6322411B2 (ja) * 2011-09-30 2018-05-09 中外製薬株式会社 複数の生理活性を有する抗原の消失を促進する抗原結合分子
BR112014010580B1 (pt) 2011-11-04 2021-01-12 Zymeworks, Inc. constructo de fc heteromultimérico isolado, composição, uso de um constructo de fc heteromultimérico isolado, composição de ácido nucléico e método para expressar o constructo de fc heteromultimérico isolado
KR20230143201A (ko) * 2011-11-30 2023-10-11 추가이 세이야쿠 가부시키가이샤 면역 복합체를 형성하는 세포내로의 운반체（캐리어）를 포함하는 의약
EP3517548A1 (en) * 2012-03-13 2019-07-31 NovImmune S.A. Readily isolated bispecific antibodies with native immunoglobulin format
EP2857419B1 (en) * 2012-05-30 2021-01-13 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule for eliminating aggregated antigens
WO2013180200A1 (ja) * 2012-05-30 2013-12-05 中外製薬株式会社 標的組織特異的抗原結合分子
MX366910B (es) 2013-03-15 2019-07-30 Janssen Biotech Inc Metodos de fabricacion para controlar el contenido de lisina c-terminal, galactosa y acido sialico en proteinas recombinantes.
JP6236948B2 (ja) * 2013-07-17 2017-11-29 東ソー株式会社 抗体精製用溶出液および当該溶出液を用いた抗体精製方法
JP6456831B2 (ja) * 2013-09-04 2019-01-23 プロテノバ株式会社 イムノグロブリン結合ドメイン多量体
JP2016538275A (ja) * 2013-11-04 2016-12-08 グレンマーク ファーマシューティカルズ， エセ．アー． Ｔ細胞再標的化ヘテロ二量体免疫グロブリン（ｈｅｔｅｒｏ−ｄｉｍｅｒｉｃ ｉｍｍｕｎｏｇｌｏｂｕｌｉｎ）の製造
MX2016010951A (es) * 2014-03-05 2016-11-29 Ucb Biopharma Sprl Proteinas de fc multimericas.
JP6685924B2 (ja) * 2014-04-11 2020-04-22 メディミューン，エルエルシー システイン操作抗体を含むコンジュゲート化合物
CA2945882A1 (en) 2014-04-16 2015-10-22 Ucb Biopharma Sprl Multimeric fc proteins
KR101860280B1 (ko) * 2014-12-19 2018-05-21 추가이 세이야쿠 가부시키가이샤 항-마이오스타틴 항체, 변이체 Fc 영역을 함유하는 폴리펩타이드, 및 사용 방법
KR102605798B1 (ko) * 2015-02-05 2023-11-23 추가이 세이야쿠 가부시키가이샤 이온 농도 의존적 항원 결합 도메인을 포함하는 항체, Fc 영역 개변체, IL-8에 결합하는 항체, 및 그들의 사용
WO2017011342A1 (en) * 2015-07-10 2017-01-19 Abbvie Inc. Igm-or-ige-modified binding proteins and uses thereof
EP3307321A4 (en) 2015-08-26 2019-04-17 Bison Therapeutics Inc. MULTISPECIFIC ANTIBODY PLATFORM AND ASSOCIATED METHODS
GB201515745D0 (en) 2015-09-04 2015-10-21 Ucb Biopharma Sprl Proteins

Similar Documents

Publication Publication Date Title
JP2020522266A5 (enExample)
US12152076B2 (en) Bispecific and monospecific antibodies using novel anti-PD-1 sequences
JP7450535B2 (ja) 単一特異性抗体から多重特異性抗体を生成させるための方法
JP2022544760A5 (enExample)
JP2025094049A (ja) 改善された単鎖可変断片のための材料及び方法
RU2018108103A (ru) КОНСТРУКЦИИ, ИМЕЮЩИЕ SIRP-α ДОМЕН ИЛИ ЕГО ВАРИАНТ
IL270897B1 (en) Immunoglobulin regions that allow heterodimerization
EP3641815A1 (en) A TARGET CELL-DEPENDENT T CELL ENGAGING AND ACTIVATION ASYMMETRIC HETERODIMERIC Fc-ScFv FUSION ANTIBODY FORMAT FOR CANCER THERAPY
US20180371089A1 (en) Asymmetric heterodimeric fc-scfv fusion anti-globo h and anti-cd3 bispecific antibody and uses thereof in caner therapy
AU2024275316A1 (en) Ch3 domain variant or bispecific antibody comprising same
RU2019144115A (ru) Cконструированные мультиспецифические антитела и другие мультимерные белки с асимметричными мутациями в области ch2-ch3
WO2024221187A1 (en) Heteromultimer polypeptides
RU2023105130A (ru) Антителоподобная молекула, включающая гетеродимер на основе белка CD1b (кластер дифференцировки 1) человека
WO2025245176A1 (en) Multispecific antibody constructs
HK40031028A (en) Method for generating multispecific antibodies from monospecific antibodies
HK40031028B (zh) 从单特异性抗体生成多特异性抗体的方法
CN118742566A (zh) 包含用于免疫应答的增强型多特异性结合剂的组合物